I missed the ADXS run. Truly amazing period for them. Too bad it was derailed. Some may think Dan O' Connor is suspect bringing his old team associates from Advaxis and ImClone (which was sold to Eli Lilly) to Oncosec, but he is simply trying to commercialize Oncosec's TAVO platform. He has a good shot and I don't want to miss the boat here. It has been a rough ride but the science is solid and the prospects are extremely good. In the near-term I am eyeing sec filings for quarterly tute holdings in the next few weeks.
News 
Market Data 
Discover 
